Page 150 - Read Online

Page 18 Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46

DECLARATIONS
Authors’ contributions
Reviewed literature, and critically reviewed, analyzed and interpreted the current state-of-the-art data:
Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M

Availability of data and materials
Not applicable.

Financial support and sponsorship
Not applicable.

Conflicts of interest
Spiliopoulou P declared that there are no conflicts of interest. Kaur P, Hammett T, and Lahn M are full-time
employees of iOnctura SA; Di Conza G and Lahn M holds stocks in iOnctura SA.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors
per NCCN guidelines with the level of evidence. Cancers 2020;12:738. DOI PubMed PMC
2. Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential,
mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int
2023;23:64. DOI PubMed PMC
3. Pai SI, Cesano A, Marincola FM. The paradox of cancer immune exclusion: immune oncology next frontier. In: Lee PP, Marincola
FM, editors. Tumor microenvironment. Cham: Springer International Publishing; 2020. pp. 173-95. DOI PubMed PMC
4. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T
cell-inflamed versus non-T cell-inflamed tumor microenvironment. In: Kalinski P, editor. Tumor immune microenvironment in
cancer progression and cancer therapy. Cham: Springer International Publishing; 2017. pp. 19-31. DOI PubMed PMC
5. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity
2023;56:2188-205. DOI PubMed
6. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30. DOI PubMed
7. Clifton GT, Rothenberg M, Ascierto PA, et al. Developing a definition of immune exclusion in cancer: results of a modified Delphi
workshop. J Immunother Cancer 2023;11:e006773. DOI PubMed PMC
8. Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer
Cell 2021;39:845-65.e7. DOI
9. Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer 2019;19:215-27. DOI
PubMed PMC
10. Bu X, Mahoney KM, Freeman GJ. Learning from PD-1 resistance: new combination strategies. Trends Mol Med 2016;22:448-51.
DOI PubMed PMC
11. Sharma A, Rudra D. Emerging functions of regulatory T cells in tissue homeostasis. Front Immunol 2018;9:883. DOI PubMed
PMC
12. Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision
therapies. J Immunother Cancer 2021;9:e002591. DOI PubMed PMC
+
+
13. Shevach EM. CD4 CD25 suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400. DOI PubMed
14. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21:903-14. PubMed PMC
15. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723-37.
PubMed PMC